Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The biotech disclosed more data for its experimental coronavirus vaccine.

Why Novavax Stock Rose Today as the Market Crashed

Novavax, Inc. (NASDAQ: NVAX) shares were moving solidly higher Thursday following the publication of detailed results of the Phase 1 study of its coronavirus vaccine candidate in the New England Journal of Medicine.

Novavax Analyst Says Coronavirus Vaccine 'Promising': 6 Takeaways From Phase 1 Results

GlaxoSmithKline

Sanofi

Novavax and the team of Sanofi and GlaxoSmithKline separately reported trial advances with their Covid vaccine candidates, sending shares of NVAX and SNY rising in early trading Thursday.
The post Novavax Posts Good Covid Vaccine Data; Sanofi, GlaxoSmithKline Start First Human Tests appeared first on Investor's Business Daily.

Novavax Posts Good Covid Vaccine Data; Sanofi, GlaxoSmithKline Start First Human Tests

Arbutus Biopharma

AstraZeneca

Johnson & Johnson

Moderna

Pfizer

America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic.

As CDC Issues Notice, Stock Market Bets Which Company Gets First COVID-19 Vaccine FDA Approval

Novavax Inc. NVAX, -2.07% released more extensive data on its Phase 1 trial of a vaccine for COVID-19 Wednesday, and shares rose about 4% in after-hours trading.

Novavax publishes more data on vaccine study, stock rises 4%

NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera

Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine

Investors are betting the urgent need to end the Covid-19 pandemic, which has become the biggest healthcare and economic crisis of recent times, will translate into big profits for companies that successfully develop a safe, effective, and affordable vaccine. Our indicative Theme of Coronavirus.

Novavax And Moderna Are Big Covid Vaccine Stock Bets This Year

Inovio Pharmaceuticals

One of these high-flying biotechs is set up to stand out over the long-term.

Better Coronavirus Stock: Inovio Pharmaceuticals or Novavax?

As one of the viable Covid-19 vaccine producers, Novavax was a Cinderella story of 2020. But a harsh reality check is making NVAX stock look less credible.

Novavax’s Cinderella Tale is Heading Toward an Alternative Ending

Novavax, Inc. (NASDAQ: NVAX) is among the companies developing a coronavirus vaccine, and unlike the frontrunners that have advanced their respective vaccine candidates into Phase 3 trials, Novavax is still in Phase 2.

Every Coronavirus Vaccine Deal Novavax Has Negotiated

Novavax (NVAX) signs a contract with the Government of Canada for supplying up to 76 million doses of its COVID-19 vaccine NVX-CoV2373, if approved.

Novavax to Supply Coronavirus Vaccine to Canadian Government

With biotech companies, regardless of what drug, therapy or vaccine being worked on, clinical trials are vital and that's certainly the case with NVX-CoV2373 stepping into the second stage. This trial is relevant because it will include testing on humans in age groups deemed highly susceptible to contracting Covid-19 and dying from the illness.

This Novavax Stock Pullback May Be a Massive Opportunity

Novavax: COVID-19 Gave It Fuel, But It's Running Near Empty

Novavax, which already has supply deals with the U.S. and U.K., announced an agreement in principle to supply up to 76 million doses of its coronavirus vaccine candidate to Canada.

Novavax Inks Deal To Sell Coronavirus Vaccine To Canada; Stock Jumps

Vaxart

Are these two COVID-19 vaccine stocks still worth buying?

These 2 Shocking Stocks Have Outperformed the S&P in 2020 -- by a Lot

The agreement is contingent on the vaccine getting a license from Health Canada, the company said.

Canada to purchase 76 million doses of Novavax coronavirus vaccine, company says

•  Canadian government to purchase up to 76 million doses of NVX-CoV2373

Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine

BioNTech SE

Heat Biologics

COVID-19 vaccine stocks have gotten slammed this month.

Has The COVID-19 Vaccine Stock Bubble Burst?

Apple

Activision Blizzard

DraftKings

Anaplan Inc

Block

We used TipRanks analyst ranking service to pinpoint Wall Street's best-performing analysts.

With the market back at a record, Wall Street's top analysts think these stocks can go even higher

Looking at clinical trial data and other key elements offers us the answer.

Are These the 3 Best Coronavirus Stocks to Buy Now?

Missed the spectacular rally on this coronavirus vaccine stock? Now is the time to buy some shares.

Want to Buy Novavax Stock on the Dip? Now's the Time

NVAX stock has been among the hottest stocks in 2020, but it still remains a risky investment
The post Novavax Is Conducting Clinical Trials: The Ride In NVAX Stock Will Continue To Be Wild appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					America’s #1 Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company				
			
					
				
					Radical New Battery Could Dismantle Oil Markets

Novavax Is Conducting Clinical Trials: The Ride In NVAX Stock Will Continue To Be Wild

NVAX stock appears to be a decent wager in the vaccine sweepstakes despite recent volatility and some insider selling.
The post Novavax Is Worth a Bet in the Vaccine Race appeared first on InvestorPlace.

Novavax Is Worth a Bet in the Vaccine Race

The key variable in this race is not the phase 3 trial, but which company has enough positive data for an Emergency Use Authorization.

Why Novavax's Coronavirus Vaccine Might Be First to Market

Novavax stock has been a top performer in 2020, but concern it may lose the race for the first Covid-19 vaccine has NVAX stock slumping.
The post Novavax’s Slump Is a Huge Buying Opportunity appeared first on InvestorPlace.

News for Novavax Stock (NVAX)